Takeda’s ADZYNMA Approved by FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura
Takeda has received FDA approval for ADZYNMA (ADAMTS13, recombinant-krhn) for both prophylactic and on-demand treatment in adults and pediatric patients diagnosed with congenital thrombotic thrombocytopenic purpura (cTTP). This marks a significant milestone as ADZYNMA is the first and only recombinant ADAMTS13 (rADAMTS13) protein sanctioned by the FDA. It addresses an unmet medical need by replacing the deficient ADAMTS13 enzyme in individuals with cTTP.
“People grappling with cTTP confront se...